Assessment of the insecticidal activity of afoxolaner against Aedes aegypti in dogs treated with NexGard.

Abstract

Twelve healthy dogs were studied in this parallel group, blinded, randomised, and negative controlled efficacy study. On Day -1, the 12&#x2009;dogs included were ranked within sex in descending order of individual pre-treatment (Day -5) fed mosquito counts and randomly allocated by blocks of two dogs to the untreated control group or the afoxolaner-treated group. NexGard(Merial, now part of Boehringer Ingelheim Animal Health) was administered orally on Day 0 in accordance with the European label instructions. On Days 1, 7, 14, 21 and 28, all dogs were exposed for a duration of 1&#x2009;hour to 50&#x2009;&#xb1;&#x2009;5 unfed Aedes aegypti females. After each exposure, mosquitoes were collected after 1&#x2009;hour and assessed for viability during collection and at 24&#x2009;&#xb1;&#x2009;2&#x2009;hours. The arithmetic (and geometric) mean values of live fed mosquito counts at 24&#x2009;hours after the exposure periods for the negative control group ranged from 33.7 (32.3) to 49.8 (49.7), indicating that this was a vigorous mosquito strain. There was no significant difference between control and treated groups in the number of live and fed mosquitoes at each 1&#x2009;hour post-exposure collection time. Based on arithmetic and geometric mean values at 24&#x2009;hours after each exposure, significantly fewer live fed mosquitoes were recorded in the treated group, compared to the negative control group, throughout the study (p&#x2009;<&#x2009;0.001). The afoxolaner insecticidal efficacy against A. aegypti varied from 98% (Day 2) to 75.3% (Day 29) based on arithmetic means, and 98.7% (Day 2) to 89.8% (Day 29) based on geometric means.